Oncotarget Authority Increases With A Higher Impact Rating

Recently Oncotarget announced that their new impact factor is 5.168. The number of times the average article, published in the last two years, is cited in a journal determines the impact factor; Oncotarget’s articles were cited 30,241 times in 2016. Important journals typically have higher impact factors than less important journals.In the 2015-2016 time period, Oncotarget had more articles published than any other oncology journal, with significantly more than the second place journal.Oncotarget is a peer-reviewed medical journal published weekly.

The focus is on cancer research, tumor development, treatment protocols and everything related to cancer. Oncotarget also publishes papers covering age-related diseases, immunology and pathology. Research papers are published quickly, as long as they meet Oncotarget’s requirements and pass the peer review process. Approved papers appear online in as little as five days.Papers published by Oncotarget are open access, published under a Creative Commons Attribution 3.0 License.

Authors retain the copyright, however, the journal is available online for anyone to read. People may also use or reprint the article as long as they give credit to the authors and Oncotarget. While Oncotarget’s articles are reprinted by websites that aggregate research papers, other articles, such as a recent article that claims leukemia may be halted by Vitamin C, are interesting to the public as well as other cancer researchers.Mikhail V. Blagosklonny and Andrei V. Gudkov of the Roswell Park Cancer Institute are the journal’s editors-in-chief. The founding editorial board consists of prominent individuals from Harvard, Johns Hopkins University and cancer research centers.

Who is Mikhail Blagosklonny?

It is highly possible you have never heard of Mikhail Blagosklonny. Exactly who is he and why should we care? The truth is, if you are of an advanced age and/or have recently been diagnosed with cancer, you should know all about this man. Why? Keep reading and we shall tell you.

Scientists who study cancer and the aging process are of great importance to our society, especially nowadays. Well, that is precisely what Mikhail Blagosklonny does. Back in the year 2009, he was the leading authority on oncology in New York at the Roswell Park Cancer Institute. Not only does he have an M.D. in internal medicine, but he also is proud to have earned a PhD in medicines of the experimental nature. Read more on templeofthecave.com

It is important to talk about how Mikhail Blagosklonny has made significant strides in cancer treatment research. This includes a type of cancer therapy in which normal cells are protected from becoming damaged. To learn all about the different drugs he has helped develop to aide cancer patients, you can read the publication “Cancer Biology & Therapy,” for which he acts as the associate editor.

The other pertinent area that Dr. Blagosklonny studies with a passion is the aging process and all matters related to it. A hypothesis that he is fond of is TOR signaling and its possible role in aging. Another publication he edits, relative to aging, is one called simply “Aging.” One facet of aging that this gentleman is knowledgeable in is the drug rapamycin, that is aka a heavily-effective cancer drug. He is experimenting with whether or not this same drug can be used for life extension in general.

The good doctor’s expertise does not stop there. He is also extremely schooled in hematology, clinical trials, and other facets of oncology. He is instrumental in something known as Phase 1, the trial of an inhibitor called histone deacetylase. This theory and professional expertise is aimed at those patients that possess refreactory neoplasms. The key purpose of these trials was to explain what dosage patients can actually tolerate when this drug is administered. Dr. Blagosklonny partnered with several other authors to document this research. That is surely good news for patients who will benefit from the findings. View his LinkedIn profile

When doing further research on cell death and classification, it is important to understand the different cell types. The doctor and his fellow co-authors discuss these types and define them. Then they get into the various morphologies and explain the related terminology. To the average person all of this may seem inconsequential; however, to those people who have cancer this information is quite valuable. The same is true of all the cancer-related research done by Dr. Blagosklonny and his colleagues. To read more, simply do an online search for either the doctor or the various related subjects.

If you are an older citizen, don’t forget to also look up this man’s research findings on aging. He tackles this topic with just as much knowledge and passion as he does his cancer research. The resulting information is very valuable.